🚀 VC round data is live in beta, check it out!
Alembic Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alembic Pharmaceuticals and similar public comparables like Biohaven, Hanall Biopharma, Chongqing Genrix, Bora Pharmaceuticals and more.
Alembic Pharmaceuticals Overview
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
Founded
2010
HQ
Employees
16.6K
Website
Sectors
Financials (LTM)
EV
$2B
Alembic Pharmaceuticals Financials
Alembic Pharmaceuticals reported last 12-month revenue of $803M and EBITDA of $130M.
In the same LTM period, Alembic Pharmaceuticals generated $585M in gross profit, $130M in EBITDA, and $74M in net income.
Revenue (LTM)
Alembic Pharmaceuticals P&L
In the most recent fiscal year, Alembic Pharmaceuticals reported revenue of $790M and EBITDA of $119M.
Alembic Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $803M | XXX | $790M | XXX | XXX | XXX |
| Gross Profit | $585M | XXX | $473M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $130M | XXX | $119M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $74M | XXX | $68M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | — | — | $120M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alembic Pharmaceuticals Stock Performance
Alembic Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Alembic Pharmaceuticals' stock price is $8.44.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 5.2% | XXX | XXX | XXX | $0.35 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlembic Pharmaceuticals Valuation Multiples
Alembic Pharmaceuticals trades at 2.2x EV/Revenue multiple, and 13.9x EV/EBITDA.
EV / Revenue (LTM)
Alembic Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Alembic Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate Alembic Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alembic Pharmaceuticals has a P/E ratio of 22.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | 15.1x | XXX | XXX | XXX |
| EV/EBIT | 18.7x | XXX | 20.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 22.4x | XXX | 24.4x | XXX | XXX | XXX |
| EV/FCF | 39.6x | XXX | (35.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alembic Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alembic Pharmaceuticals Margins & Growth Rates
Alembic Pharmaceuticals' revenue in the last 12 month grew by 11%.
Alembic Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Alembic Pharmaceuticals' rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alembic Pharmaceuticals' rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alembic Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alembic Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alembic Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohaven | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| RAPT Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alembic Pharmaceuticals M&A Activity
Alembic Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alembic Pharmaceuticals was on XXXXXXXX, XXXXX. Alembic Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alembic Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlembic Pharmaceuticals Investment Activity
Alembic Pharmaceuticals invested in XXX companies to date.
Alembic Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Alembic Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alembic Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alembic Pharmaceuticals
| When was Alembic Pharmaceuticals founded? | Alembic Pharmaceuticals was founded in 2010. |
| Where is Alembic Pharmaceuticals headquartered? | Alembic Pharmaceuticals is headquartered in India. |
| How many employees does Alembic Pharmaceuticals have? | As of today, Alembic Pharmaceuticals has over 16K employees. |
| Who is the CEO of Alembic Pharmaceuticals? | Alembic Pharmaceuticals' CEO is Chirayu R. Amin. |
| Is Alembic Pharmaceuticals publicly listed? | Yes, Alembic Pharmaceuticals is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Alembic Pharmaceuticals? | Alembic Pharmaceuticals trades under APLLTD ticker. |
| When did Alembic Pharmaceuticals go public? | Alembic Pharmaceuticals went public in 2011. |
| Who are competitors of Alembic Pharmaceuticals? | Alembic Pharmaceuticals main competitors are Biohaven, Hanall Biopharma, Chongqing Genrix, Bora Pharmaceuticals. |
| What is the current market cap of Alembic Pharmaceuticals? | Alembic Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of Alembic Pharmaceuticals? | Alembic Pharmaceuticals' last 12 months revenue is $803M. |
| What is the current revenue growth of Alembic Pharmaceuticals? | Alembic Pharmaceuticals revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Alembic Pharmaceuticals? | Current revenue multiple of Alembic Pharmaceuticals is 2.2x. |
| Is Alembic Pharmaceuticals profitable? | Yes, Alembic Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alembic Pharmaceuticals? | Alembic Pharmaceuticals' last 12 months EBITDA is $130M. |
| What is Alembic Pharmaceuticals' EBITDA margin? | Alembic Pharmaceuticals' last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Alembic Pharmaceuticals? | Current EBITDA multiple of Alembic Pharmaceuticals is 13.9x. |
| What is the current FCF of Alembic Pharmaceuticals? | Alembic Pharmaceuticals' last 12 months FCF is $46M. |
| What is Alembic Pharmaceuticals' FCF margin? | Alembic Pharmaceuticals' last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Alembic Pharmaceuticals? | Current FCF multiple of Alembic Pharmaceuticals is 39.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.